Coloplast Statistics

Total Valuation

Coloplast has a market cap or net worth of EUR 18.21 billion. The enterprise value is 21.36 billion.

Market Cap	18.21B
Enterprise Value	21.36B

Important Dates

The next estimated earnings date is Tuesday, August 19, 2025.

Earnings Date	Aug 19, 2025
Ex-Dividend Date	May 8, 2025

Share Statistics

Current Share Class	207.17M
Shares Outstanding	n/a
Shares Change (YoY)	+1.60%
Shares Change (QoQ)	-0.04%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	142.57M

Valuation Ratios

The trailing PE ratio is 29.89 and the forward PE ratio is 25.49.

PE Ratio	29.89
Forward PE	25.49
PS Ratio	4.89
PB Ratio	8.02
P/TBV Ratio	n/a
P/FCF Ratio	27.01
P/OCF Ratio	21.61
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.29, with an EV/FCF ratio of 31.69.

EV / Earnings	35.07
EV / Sales	5.74
EV / EBITDA	18.29
EV / EBIT	21.25
EV / FCF	31.69

Financial Position

The company has a current ratio of 0.95, with a Debt / Equity ratio of 1.43.

Current Ratio	0.95
Quick Ratio	0.57
Debt / Equity	1.43
Debt / EBITDA	2.78
Debt / FCF	4.82
Interest Coverage	9.07

Financial Efficiency

Return on equity (ROE) is 27.42% and return on invested capital (ROIC) is 11.45%.

Return on Equity (ROE)	27.42%
Return on Assets (ROA)	9.64%
Return on Invested Capital (ROIC)	11.45%
Return on Capital Employed (ROCE)	19.65%
Revenue Per Employee	222,559
Profits Per Employee	36,386
Employee Count	16,639
Asset Turnover	0.57
Inventory Turnover	2.45

Taxes

In the past 12 months, Coloplast has paid 261.40 million in taxes.

Income Tax	261.40M
Effective Tax Rate	30.03%

Stock Price Statistics

The stock price has decreased by -28.17% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-28.17%
50-Day Moving Average	87.26
200-Day Moving Average	104.72
Relative Strength Index (RSI)	37.33
Average Volume (20 Days)	134

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Coloplast had revenue of EUR 3.73 billion and earned 609.13 million in profits. Earnings per share was 2.70.

Revenue	3.73B
Gross Profit	2.52B
Operating Income	1.01B
Pretax Income	870.54M
Net Income	609.13M
EBITDA	1.13B
EBIT	1.01B
Earnings Per Share (EPS)	2.70

Full Income Statement

Balance Sheet

The company has 97.72 million in cash and 3.25 billion in debt, giving a net cash position of -3.15 billion.

Cash & Cash Equivalents	97.72M
Total Debt	3.25B
Net Cash	-3.15B
Net Cash Per Share	n/a
Equity (Book Value)	2.27B
Book Value Per Share	10.09
Working Capital	-67.03M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 842.79 million and capital expenditures -168.64 million, giving a free cash flow of 674.15 million.

Operating Cash Flow	842.79M
Capital Expenditures	-168.64M
Free Cash Flow	674.15M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 67.52%, with operating and profit margins of 26.99% and 16.35%.

Gross Margin	67.52%
Operating Margin	26.99%
Pretax Margin	23.36%
Profit Margin	16.35%
EBITDA Margin	30.33%
EBIT Margin	26.99%
FCF Margin	18.09%

Dividends & Yields

This stock pays an annual dividend of 2.95, which amounts to a dividend yield of 3.59%.

Dividend Per Share	2.95
Dividend Yield	3.59%
Dividend Growth (YoY)	4.73%
Years of Dividend Growth	16
Payout Ratio	109.07%
Buyback Yield	-1.60%
Shareholder Yield	1.99%
Earnings Yield	3.35%
FCF Yield	3.70%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on December 19, 2012. It was a forward split with a ratio of 5.

Last Split Date	Dec 19, 2012
Split Type	Forward
Split Ratio	5

Scores

Coloplast has an Altman Z-Score of 5.13 and a Piotroski F-Score of 6.

Altman Z-Score	5.13
Piotroski F-Score	6